Quinidine CAS 56-54-2 Anti-arrhythmic drugs Pharnmaceutical Intermediates

Profile

Product Name: Quinidine

Synonyms: (8R,9S)-6'-Methoxycinchonan-9-ol;(8r,9s)-quinidine;(95)-cinchonan-9-0;(9s)-6’-methoxycinchonan-9-ol;(9S)-6'-Methoxycinchonan-9-ol;2-Quinuclidinemethanol, alpha-(6-methoxy-4-quinolyl)-5-vinyl-;6-Methoxy-alpha-(5-vinyl-2-quinuclidinyl)-4-quinolinemethanol;6'-Methoxycinchonan-9-ol

CAS: 56-54-2

MF: C20H24N2O2

MW: 324.42

EINECS: 200-279-0

Product Categories: chiral;Alkaloids;Alkoxyquinolines;Biochemistry;for Resolution of Acids;Optical Resolution;Quinoline Alkaloids;Quinolines;Synthetic Organic Chemistry;Intermediates & Fine Chemicals;Pharmaceuticals;Cinchona AlkaloidsMonovalent Ion Channels;Chiral Catalysts, Ligands, and Reagents;Other Sodium Channel Modulators;Privileged Ligands and Complexes;Sodium Channel Modulators;Chiral Reagents;Heterocycles;DURAQUIN

Mol File: 56-54-2.mol

Description

Quinidine as membrane inhibitors of antiarrhythmic drugs, can directly act on the myocardial cell membrane, can significantly prolong the myocardial refractory period, reduce the autonomy, conduction and myocardial contractility, especially for non-sinus rhythm of the role of strong, Sinoatrial node action potential of the same or prolonged, reducing conduction velocity, prolonged effective refractory period, reduce excitability, the atrial refractory period prolonged significantly compared with the ventricle, shortening atrioventricular junction refractory period.

Indications

Oral application for atrial premature beats, atrial fibrillation, paroxysmal supraventricular tachycardia, Wolff-Parkinson-White syndrome with ventricular arrhythmias, ventricular premature beats, ventricular tachycardia and fibrillation or atrial flutter after electrical conversion Maintenance treatment. Intramuscular and intravenous injection has not.